GGrantIndex
← Leaderboards

Conor Caffrey

University Of California, San Francisco

$4,887,893
Attributed
$9,552,070
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,552,070 · 11

By mechanism

U01$4,559,463 · 1
R21$3,645,945 · 9
R01$1,346,662 · 1

Top collaborators

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations

Research focus

Pharmaceutical PreparationsParasitesDesignDrug DiscoveryNovel TherapeuticsProgramsStructureIn VitroSmall MoleculeBaseDrug TargetingSeriesParasitic DiseasesInfectionFutureWorld Health OrganizationSchistosome ParasiteResponseSchistosomiasisDrug DevelopmentDrug KineticsDrug ResistancePraziquantelCells

Grant awards (21)

Development of a MT-stabilizing agent for the treatment of tauopathies$2,250,355
U01 · FY2025 · AG · contact PI
New tools to facilitate drug discovery for pathogen proteasomes$438,500
R21 · FY2025 · AI
Development of a MT-stabilizing agent for the treatment of tauopathies$2,309,108
U01 · FY2024 · AG · contact PI
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis$197,500
R21 · FY2023 · AI · contact PI
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis$237,000
R21 · FY2022 · AI · contact PI
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis$197,500
R21 · FY2022 · AI · contact PI
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis$237,000
R21 · FY2021 · AI · contact PI
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$252,094
R21 · FY2020 · AI
Reasoning with chemically induced dynamic phenotypes in whole-organism assays$233,375
R21 · FY2020 · AI
Translational development of cysteine protease inhibitors to treat hookworm disease$196,875
R21 · FY2020 · AI · contact PI
Translational development of cysteine protease inhibitors to treat hookworm disease$236,250
R21 · FY2019 · AI · contact PI
Reasoning with chemically induced dynamic phenotypes in whole-organism assays$204,803
R21 · FY2019 · AI
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$193,750
R21 · FY2019 · AI · contact PI
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$189,122
R21 · FY2019 · AI
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$232,500
R21 · FY2018 · AI · contact PI
Defining the death transcriptome of Schistosoma mansoni to construct a molecular drug screen$182,750
R21 · FY2018 · AI · contact PI
Defining the death transcriptome of Schistosoma mansoni to construct a molecular drug screen$232,500
R21 · FY2017 · AI · contact PI
Exploring statins as a small molecule therapy for treatment of schistosomiasis$184,426
R21 · FY2013 · AI · contact PI
An automated high throughput phenotypic screen for schistosomiasis drug discovery$428,854
R01 · FY2012 · AI · contact PI
An automated high throughput phenotypic screen for schistosomiasis drug discovery$423,139
R01 · FY2011 · AI · contact PI
An automated high throughput phenotypic screen for schistosomiasis drug discovery$494,669
R01 · FY2010 · AI · contact PI